Greg Yothers, PhD

My primary research interest is the design, implementation and analysis of phase II and III clinical trials for cancer research.  My work with the NRG Oncology clinical trials group has included trials evaluating therapies for the treatment of colon, rectal, and breast cancer.  The focus of my methodological research has been the development of statistical methodologies for identifying a subset of a clinical trial population where a treatment is effective.

 I am one of the Primary Investigators for the NRG Oncology Statistics
and Data Management Center - a clinical trials research group comprising
200+ employees.  I am responsible for
oversight of the statisticians supporting the scientific committees of NRG
Oncology.

2003 | University of Pittsburgh, Pittsburgh, PA | Doctor of Philosophy in Statistics

1998 | University of Pittsburgh, Pittsburgh, PA | Master of Arts in Statistics
1981 | Pennsylvania State University, State College, PA | Bachelor of Science in Mathematics

 
  Okunieff, P., Casey-Sawicki, K., Lockney, N. A., Hoppe, B. A.,
Enderling, H., Pinnix, C., . . . Kachnic, L. (2018). Report from the SWOG Radiation Oncology Committee: Research Objectives Workshop 2017. Clinical Cancer Research. Aug 1, 2018. 24(15): 3500-3509.
doi:10.1158/1078-0432.CCR-17-3202
  
  
  Kim, S. R., Song, N., Yothers, G., Gavin, P. G., Allegra, C. J.,
Paik, S., & Pogue-Geile, K. L. (2018). Tumour sidedness and intrinsic
subtypes in patients with stage II/III colon cancer: Analysis of NSABP C-07
(NRG Oncology). British Journal of
Cancer, 118(5), 629-633. doi:10.1038/bjc.2017.448
  
   
  Blum, J. L., Flynn, P. J., Yothers, G., Asmar, L., Geyer, C. E.,
Jacobs, S. A., . . . Wolmark, N. (2017). Anthracyclines in early breast
Cancer: The ABC Trials—USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49
(NRG Oncology). Journal of Clinical
Oncology, 35(23), 2647-2655.
doi:10.1200/JCO.2016.71.4147
   
  
  Kunitake, H., Russell, M. M., Zheng, P., Yothers, G., Land, S.
R., Petersen, L., . . . Ganz, P. A. (2017). Quality of life and symptoms in
long-term survivors of colorectal cancer: results from NSABP protocol LTS-01.
JOURNAL OF CANCER SURVIVORSHIP, 11(1), 111-118. doi:10.1007/s11764-016-0567-y
   
  
  Sinicrope, F. A., Shi, Q., Allegra, C. J., Smyrk, T. C.,
Thibodeau, S. N., Goldberg, R. M., . . . Alberts, S. R. (2017). Association
of DNA mismatch repair and mutations in BRAF and KRAS with survival after
recurrence in stage III colon cancers: A secondary analysis of 2 randomized
clinical trials. JAMA Oncology, 3(4), 472-480. doi:10.1001/jamaoncol.2016.5469
   
  
  Song, N., Pogue-Geile, K. L., Gavin, P. G., Yothers, G., Kim, S.
R., Johnson, N. L., . . . Paik, S. (2016). Clinical outcome from oxaliplatin
treatment in stage II/III colon cancer according to intrinsic subtypes:
Secondary analysis of NSABP C-07/NRG oncology randomized clinical trial. JAMA Oncology, 2(9), 1162-1169. doi:10.1001/jamaoncol.2016.2314
  

Link to Greg Yothers complete bibliography...